Nilesh Gajanan Bajad

Employment

Employment history is unavailable.

Education

• Indian Institute of Technology (BHU) Varanasi PhD (Pharmaceutical Sciences)
  2021 - Present
• Indian Institute of Technology BHU Varanasi M. Pharm (Pharmaceutical Chemistry)
  2019 - 2021
• Government College of Pharmacy, Amravati B. Pharm
  2015 - 2019

Projects & Funding

Projects & funding information is unavailable.

Publications (16)

• Targeting Histone Deacetylase 2 in Alzheimer’s Disease: From Molecular Insights to Epigenetic Therapeutic Opportunities
  Molecular Neurobiology 2026 DOI: 10.1007/s12035-026-06078-2
  +Save
• Development of Donor–Acceptor Architecture-Based Potential Theranostic Fluorescent Probes for Alzheimer’s Disease
  ACS Chemical Neuroscience 2025 DOI: 10.1021/acschemneuro.5c00092
  +Save
• Discovery of pyrazoline analogs as multi-targeting cholinesterase, β-secretase and Aβ aggregation inhibitors through lead optimization strategy
  International Journal of Biological Macromolecules 2025 DOI: 10.1016/j.ijbiomac.2025.140436
  +Save
• Development of multifunctional fluorescence-emitting potential theranostic agents for Alzheimer's disease
  Talanta 2025 DOI: 10.1016/j.talanta.2025.127574
  +Save
• Development of multi-targetable chalcone derivatives bearing N-aryl piperazine moiety for the treatment of Alzheimer's disease
  Bioorganic Chemistry 2024 DOI: 10.1016/j.bioorg.2023.107082
  +Save
• Identification of novel potential cathepsin-B inhibitors through pharmacophore-based virtual screening, molecular docking, and dynamics simulation studies for the treatment of Alzheimer’s disease
  Molecular Diversity 2024 DOI: 10.1007/s11030-024-10821-z
  +Save
• Identification of potent histone deacetylase 2 (HDAC2) inhibitors through combined structure and ligand-based designs and molecular modelling approach
  Journal of Biomolecular Structure and Dynamics 2024 DOI: 10.1080/07391102.2023.2222177
  +Save
• Integrated pharmacophore-based virtual screening and molecular modeling approaches for the identification of sigma-2 receptor antagonists as novel therapeutics against Alzheimer’s disease
  Journal of Biomolecular Structure and Dynamics 2024 DOI: 10.1080/07391102.2024.2446666
  +Save
• Discovery of triazole-bridged aryl adamantane analogs as an intriguing class of multifunctional agents for treatment of Alzheimer's disease
  European Journal of Medicinal Chemistry 2023 DOI: 10.1016/j.ejmech.2023.115670
  +Save
• Recent Advances in the Development of Near-Infrared Fluorescent Probes for the in Vivo Brain Imaging of Amyloid-β Species in Alzheimer’s Disease
  ACS Chemical Neuroscience 2023 DOI: 10.1021/acschemneuro.3c00304
  +Save